EF
IMVT icon

Empowered Funds’s Immunovant IMVT Stock Holding History

Empowered Funds’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Sell
9,880
-4,676
-32% -$142K ﹤0.01% 1775
2026
Q1 		$362K Buy
14,556
+381
+3% +$9.86K ﹤0.01% 1750
2025
Q4 		$360K Buy
14,175
+610
+4% +$13.6K 0.01% 822
2025
Q3 		$219K Buy
13,565
+173
+1% +$2.8K ﹤0.01% 1688
2025
Q2 		$214K Buy
+13,392
New +$203K ﹤0.01% 1625
2023
Q3 		– Sell
-136,097
Closed -$2.58M – 1239
2023
Q2 		$2.58M Buy
+136,097
New +$2.54M 0.09% 318

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Empowered Funds's IMVT Position: Q2 2026 in Review

Empowered Funds reduced its Immunovant (IMVT) stake by 32% in Q2 2026, selling an estimated $142K and leaving 9,880 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #1775.

Empowered Funds first reported a position in IMVT in Q2 2023 and has held it in 6 quarters since. The position peaked at $2.58M in Q2 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Empowered Funds held 9,880 shares of Immunovant worth $381K as of Q2 2026.
  • Empowered Funds sold 4,676 Immunovant shares in Q2 2026, an estimated $142K.
  • Immunovant made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1775 holding.
  • Empowered Funds first reported a position in Immunovant in Q2 2023 and has held it in 6 quarters since.
  • Empowered Funds's Immunovant position peaked at $2.58M in Q2 2023.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.